Recent research headlines have placed a heavy focus on biologics, but small molecule discovery is still dominating the pharmaceutical R&D space. In fact, 62% of new drug approvals in 2021 were for small molecules. The reliability and cost-effectiveness of these therapeutics has helped them to stay relevant, even as biologics take more of the market share than in years past. And it turns out you can teach an old dog new tricks! Tried and true small molecules have undergone exciting innovation with advances in computational methods, screening technologies, and target exploration. Still, challenges remain – cost effectiveness, workflows, and data management continue to be variables that require attention and optimization in order to remain successful in small molecule drug discovery.

TransPharm can perform preclinical testing of a your newly developed small molecule drugs. Contact us today for a no-obligation consultation or a free quote.

​